ArticleDigestive diseases and sciences2025
Differences in Gastrointestinal Motility in Adults with Type 1 and Type 2 Diabetes Using Wireless Motility Capsule.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.ACG case reports journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGastrointestinal motility disorders are common in diabetes, though their prevalence and distribution have not been evaluated. The Wireless Motility Capsule (WMC) assesses transit times and pressures of the entire gastrointestinal (GI) tract in a single study. This study aimed to evaluate the prevalence and patterns of GI transit abnormalities using WMC in patients with diabetes.
methodsThis retrospective study included adult patients with Type 1 (T1D) and Type 2 Diabetes (T2D) who underwent WMC testing. Whole gut transit time (WGTT), gastric emptying time (GET), small bowel transit time (SBTT) and colon transit time (CTT) were analyzed. Univariate and multivariable analyses identified risk factors for delayed transit. The rates of diabetic complications were assessed. Kaplan-Meier estimates of mortality rates at 1, 3, and 5 years were compared for patients with T1D and T2D.
resultsA total of 475 patients (mean age of 54.4 years, 74% female) were included. Of these, 25.9% had T1D and 74.1% had T2D. Mean diabetes duration was 11.4 years. Patients with T1D had a higher mean disease duration of 21.7 years and those with T2D of 7.7 years. More than 35% of patients had HbA1c > 8 and 34% of patients had an HgbA1c between 6.5 and 7.99%. T1D patients had a higher mean HbA1c of 8.6% compared to 7.5% in T2D. Mean BMI was 32.3 in T2D and 26.5 in T1D. Mean BMI was higher in those with normal motility (32.9) than delayed motility (30.1). Delayed transit was observed in 75.8% with delayed GET (58.8%) being the most common abnormality. T2D had shorter median GET (4.4) than T1D (6.1) and longer CTT (95.9) than T1D (79.3). SBTT had an inverse correlation with HbA1c (-0.16). Microvascular complications were greater in T1D including neuropathy in 64.2%, retinopathy in 35% and nephropathy in 31.7% compared to T2D which were: neuropathy 50.3%, retinopathy 11.1% and nephropathy 19%. 7.3 and 1.1% of patients with T1D and T2D had kidney or pancreas transplants respectively. Kaplan-Meier analysis showed no significant difference in mortality in T1D vs T2D.
conclusionThis study reports the prevalence of GI motility abnormalities in patients with longer duration of diabetes, higher HbA1c, lower BMI and associated diabetes microvascular complications. Delayed gastric emptying was the most common finding with greater prevalence of GET delay in T1D vs. T2D. T2D had shorter GET but longer CTT. Mean diabetes duration was 11.4 years and > 70% of patients with diabetes had suboptimal glucose control. Microvascular complications and pancreas/kidney transplant were higher in patients with T1D. Mortality rates were not different in T1D vs T2D. Identifying GI motility disorders in diabetes can guide management to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.